EUVIMEDEUVIMED entdecken
Open Access

Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer

Robert T Galvin iD, Yan Chen iD, Yan Yuan, Tabitha Cooney, Rebecca Howell, Susan Smith iD, Michael A Arnold iD, Miriam Conces, Wendy Leisenring iD, Gregory T Armstrong iD, Joseph P Neglia iD, Lucie M Turcotte iD

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djaf005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Robert T Galvin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, MN 55455, United States. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Neoplasms, Second Primary, Cranial Irradiation, Survivors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is not known whether temporal changes in childhood cancer therapy have reduced risk of subsequent malignant neoplasms of the central nervous system (CNS), a frequently fatal late effect of cancer therapy.

Methods

Five-year survivors of primary childhood cancers diagnosed between 1970 and 1999 in the Childhood Cancer Survivor Study with CNS subsequent malignant neoplasms were identified. Cumulative incidence rates and standardized incidence ratios were compared among survivors diagnosed between 1970-1979 (n = 6223), 1980-1989 (n = 9680), and 1990-1999 (n = 8999). Multivariable models assessed risk factors for CNS subsequent malignant neoplasms.

Results

A total of 157 CNS subsequent malignant neoplasms (1970s, 52; 1980s, 63; 1990s, 42) were identified, excluding meningiomas, which were most often malignant gliomas. The proportion of survivors receiving any cranial radiotherapy exposure was reduced over time (1970s, 77.0%; 1980s, 54.3%; 1990s, 33.9%), while the proportion receiving more than 35 Gy cranial radiotherapy showed a smaller reduction (11.4%, 10.8%, and 8.5%, respectively). Twenty-year cumulative incidence and standardized incidence ratios for CNS subsequent malignant neoplasms by treatment decade were 0.32% (95% confidence interval = 0.18% to 0.46%) and 6.6 (95% CI = 5.0 to 8.7); 0.55% (95% CI = 0.41% to 0.70%) and 8.3 (95% CI = 6.6 to 10.4); and 0.43% (95% CI = 0.31% to 0.55%) and 9.2 (95% CI = 7.0 to 12.0), respectively, with no statistically significant decreases between eras. Multivariable analyses showed increased risk for cranial radiotherapy dose levels more than 10 Gy and for primary diagnoses of medulloblastoma and/or primitive neuro-ectodermal tumor (hazard ratio [HR] = 18.7, 95% CI = 9.2 to 37.9) and astrocytoma (HR = 10.1, 95% CI = 5.3 to 19.5). Three-year cumulative incidence of death after CNS subsequent malignant neoplasms, by treatment decade, were 76%, 74%, and 73%, respectively.

Conclusion

CNS subsequent malignant neoplasm incidence has not decreased despite fewer survivors exposed to CNS-directed radiotherapy. CNS subsequent malignant neoplasm remains a substantial source of mortality for affected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsNeoplasms, Second PrimaryCranial IrradiationSurvivorsCancer SurvivorsNeoplasmsHumansIncidenceFemaleMaleChildAdolescentChild, PreschoolRisk FactorsAdultInfantYoung AdultUnited StatesTime Factors

Autor:innen und Institutionen

  • Division of Pediatric Hematology and Oncology, University of Minnesota, Minneapolis, MN 55455, United States.
  • Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • School of Public Health, University of Alberta, Edmonton, AB, Canada.
  • Day One Biopharmaceuticals, Brisbane, CA 94005, United States.
  • Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
  • Department of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, United States.

ORCID-Profile: Robert T Galvin, Yan Chen, Susan Smith, Michael A Arnold, Wendy Leisenring, Gregory T Armstrong, Joseph P Neglia, Lucie M Turcotte

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Cancer Center
  • St Jude Children's Research Hospital
  • St Jude Children’s Research Hospital
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Galvin, R. T., Chen, Y., Yuan, Y., Cooney, T., Howell, R., Smith, S., Arnold, M. A., Conces, M., Leisenring, W., Armstrong, G. T., Neglia, J. P., & Turcotte, L. M. (2025). Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf005

Vancouver

Galvin RT, Chen Y, Yuan Y, Cooney T, Howell R, Smith S, et al. Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf005

BibTeX
@article{Galvin2025,
  author = {Galvin, Robert T and Chen, Yan and Yuan, Yan and Cooney, Tabitha and Howell, Rebecca and Smith, Susan and Arnold, Michael A and Conces, Miriam and Leisenring, Wendy and Armstrong, Gregory T and Neglia, Joseph P and Turcotte, Lucie M},
  title = {Temporal trends of subsequent central nervous system malignancies among survivors of childhood cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djaf005}
}
Kostenlos starten →